Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02847637 · ClinicalTrials.gov registry record · Phase 3
A Clinical Trial to Evaluate Prophylactic Emicizumab Versus no Prophylaxis in Hemophilia A Participants Without Inhibitors
A Phase 3 study, sponsored by Hoffmann-La Roche.
- Completed
- Registry status
- Phase 3
- Development phase
- 152
- Enrollment target
NCT02847637 is a Phase 3 study that has completed, run by Hoffmann-La Roche. The registered enrollment target is 152 participants.
The verdict
NCT02847637, a Phase 3 study, has completed, sponsored by Hoffmann-La Roche.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 152 participants
- Enrollment target
Study Summary
This is a randomized, global, multicenter, open-label, Phase 3 clinical study in participants with severe hemophilia A without inhibitors against Factor VIII (FVIII) who are 12 years or older. The study evaluates two prophylactic emicizumab regimens versus no prophylaxis in this population with emphasis on efficacy, safety, and pharmacokinetics.
Interventions
- DRUG Emicizumab
- DRUG Factor VIII (FVIII)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 152 participants |
| Start Date | 2016-09-27 |
| Est. Completion | 2022-05-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02847637
The ClinicalTrials.gov registry entry for NCT02847637 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 152 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Hoffmann-La Roche, which has 909 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Emicizumab is the first listed.
NCT02847637 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02847637 about?
NCT02847637 is a clinical study titled "A Clinical Trial to Evaluate Prophylactic Emicizumab Versus no Prophylaxis in Hemophilia A Participants Without Inhibitors". This is a randomized, global, multicenter, open-label, Phase 3 clinical study in participants with severe hemophilia A without inhibitors against Factor VIII (FVIII) who are 12 years or older. The study evaluates two prophylactic emicizumab regimens versus no prophylaxis in this population with emph...
What is the current status of trial NCT02847637?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 152 participants. The study started on 2016-09-27. Estimated completion is 2022-05-12.
What interventions are being tested in trial NCT02847637?
The interventions under investigation include: Emicizumab (DRUG), Factor VIII (FVIII) (DRUG).
Who is sponsoring clinical trial NCT02847637?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.